Take the Rare Disease Day Quiz!
Test your knowledge about rare diseases, which affect more people than you think.
CSL Half Year Results 2020-21
CSL Delivers Net Profit of Over $ 1.8 Billion
What to Tell the Kids About COVID-19?
A walk to kindergarten with a group of 5-year-olds gave a CSL Behring scientist an idea for a timely children’s book.
CSL COVID19 Update
CSL continues to provide medicines to patients around the world.
What is a Phase III clinical trial?
A potential hyperimmune treatment for COVID-19 reaches a regulatory milestone in testing its efficacy and safety.
First Patient Enrolled to Evaluate Potential COVID-19 Hyperimmune Medicine
As co-leader, CSL Behring is very actively involved in this project. The product for the clinical trial phase 3 was manufactu…
Opening of New Manufacturing Facility in Bern
CSL Behring had a small celebration to mark the grand opening of the facility,
Expansion Nears Completion in Switzerland
CSL Behring validates new production capacity in Bern.
CSL Delivers Net Profit of Over $2.1 Billion
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a reported net profit after tax of $2,103 million (1) for the 12 months en…